Healthcare ❯ Pharmaceuticals ❯ Weight Loss Drugs ❯ GLP-1 Agonists
Cost pressures from Lilly’s rivals alongside compounded semaglutide are forcing a reset under new CEO Maziar Mike Doustdar.
